CA3065542A1 - Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin - Google Patents

Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin Download PDF

Info

Publication number
CA3065542A1
CA3065542A1 CA3065542A CA3065542A CA3065542A1 CA 3065542 A1 CA3065542 A1 CA 3065542A1 CA 3065542 A CA3065542 A CA 3065542A CA 3065542 A CA3065542 A CA 3065542A CA 3065542 A1 CA3065542 A1 CA 3065542A1
Authority
CA
Canada
Prior art keywords
bont
toxin
melanin
skin
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065542A
Other languages
English (en)
French (fr)
Inventor
Birgitte P.S. Jacky
Shizazh Z. Malik
Joanne Wang
Yi Liu
Amy BRIDEAU-ANDERSEN
Lance E. Steward
Linh Q. Le
Edward C. Hsia
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA3065542A1 publication Critical patent/CA3065542A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
CA3065542A 2017-05-31 2018-05-30 Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin Pending CA3065542A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512792P 2017-05-31 2017-05-31
US62/512,792 2017-05-31
PCT/US2018/035025 WO2018222652A1 (en) 2017-05-31 2018-05-30 Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Publications (1)

Publication Number Publication Date
CA3065542A1 true CA3065542A1 (en) 2018-12-06

Family

ID=62683456

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065542A Pending CA3065542A1 (en) 2017-05-31 2018-05-30 Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Country Status (16)

Country Link
US (3) US10912823B2 (https=)
EP (1) EP3630298A1 (https=)
JP (1) JP7096845B2 (https=)
KR (1) KR20200011499A (https=)
CN (1) CN110891594A (https=)
AU (1) AU2018277754A1 (https=)
BR (1) BR112019025402A2 (https=)
CA (1) CA3065542A1 (https=)
CL (1) CL2019003484A1 (https=)
CO (1) CO2019014592A2 (https=)
IL (1) IL270986B (https=)
MX (1) MX2019014349A (https=)
PH (1) PH12019502721A1 (https=)
RU (1) RU2019143639A (https=)
WO (1) WO2018222652A1 (https=)
ZA (1) ZA201907916B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
KR20210097530A (ko) * 2020-01-30 2021-08-09 (주)메디톡스 Snare 복합체의 형성을 저해하는 펩티드, 및 그의 용도
KR102550756B1 (ko) * 2022-12-21 2023-07-05 (주)메디톡스 세포로부터 신경전달물질 분비를 저해하는 펩티드, 및 그의 용도
CN121511091A (zh) 2023-07-12 2026-02-10 莫茨药物股份两合公司 通过肉毒杆菌毒素的色素沉着过度病况治疗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
KR20050094817A (ko) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20120195878A1 (en) * 2011-01-28 2012-08-02 Allergan, Inc. Protocol for the administration of botulinum toxins
US20140276359A1 (en) * 2013-03-15 2014-09-18 Plum Systems Co. Apparatus and method for tissue rejuvenation
AU2014301116B2 (en) * 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
CN105683212B (zh) * 2013-08-21 2020-03-17 香港理工大学 高催化活性的基因改造梭菌属神经毒素
WO2016048689A1 (en) * 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
MX2019005833A (es) * 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
AU2018389104A1 (en) * 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

Also Published As

Publication number Publication date
IL270986B (en) 2021-07-29
JP2020522492A (ja) 2020-07-30
US20210162027A1 (en) 2021-06-03
BR112019025402A2 (pt) 2020-06-23
AU2018277754A1 (en) 2020-01-02
RU2019143639A (ru) 2021-06-30
US20230302103A1 (en) 2023-09-28
PH12019502721A1 (en) 2020-10-19
KR20200011499A (ko) 2020-02-03
CL2019003484A1 (es) 2020-05-15
EP3630298A1 (en) 2020-04-08
US20180344820A1 (en) 2018-12-06
ZA201907916B (en) 2021-05-26
WO2018222652A1 (en) 2018-12-06
CO2019014592A2 (es) 2020-06-09
MX2019014349A (es) 2020-07-28
JP7096845B2 (ja) 2022-07-06
CN110891594A (zh) 2020-03-17
IL270986A (en) 2020-01-30
RU2019143639A3 (https=) 2021-09-06
US10912823B2 (en) 2021-02-09

Similar Documents

Publication Publication Date Title
US20230302103A1 (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
US11149262B2 (en) Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
KR101041698B1 (ko) 경피성 보툴리눔 독소 조성물
JP2022008814A (ja) 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
US10245305B2 (en) Botulinum toxin therapy for skin disorders
CN102988995A (zh) 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
US20150157728A1 (en) Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
KR20190053214A (ko) 안정화된 비단백질 클로스트리듐 독소 조성물
US20100068231A1 (en) Therapeutic use of at least one botulinum neurotoxin in the treatment of pain induced by at least one anti-neoplastic agent
EP2280719B1 (en) Therapeutic use of botulinum neurotoxin type a in the treatment of pain associated with diabetic neuropathy
MX2011010335A (es) Metodos y composiciones para tratar afecciones de la piel asociadas con hiperreactividad vascular.
US20220054605A1 (en) Dissolving film for delivery of an active agent
US20240226251A1 (en) Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent
KR20260035809A (ko) 보툴리눔 독소에 의한 과색소침착 상태의 치료
KR20210008392A (ko) 국소 제제로부터의 생물학적 작용제의 전달 방법
WO2025122980A1 (en) Use of botulinum toxins for the treatment of platysma prominence
HK1182648A (en) Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived form hiv-tat
HK1140140A (en) Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived form hiv-tat
HK1162925A (en) Injectable botulinum toxin formulations